Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Harvard Business School
Mallinckrodt
Medtronic
Johnson and Johnson

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR UROLOGIC G IN PLASTIC CONTAINER

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Urologic G In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003930 ↗ Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed National Cancer Institute (NCI) Phase 1/Phase 2 1999-09-01 RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00003930 ↗ Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed Radiation Therapy Oncology Group Phase 1/Phase 2 1999-09-01 RATIONALE: Radiation therapy uses x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy and surgery may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus combination chemotherapy in treating patients who have stage II or stage III bladder cancer that can be removed by surgery.
NCT00132301 ↗ Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed Sanofi Phase 3 2006-06-01 VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00132301 ↗ Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma Completed VA Office of Research and Development Phase 3 2006-06-01 VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical prostatectomy but who are at high risk for relapse. The standard of care is surveillance, with the addition of androgen deprivation at the time of biochemical relapse. This study will assess the effect of adding early chemotherapy to the standard of care on progression free survival in Veterans at high risk for progression after prostatectomy.
NCT00138008 ↗ Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Completed Ministry of Health, Labour and Welfare, Japan Phase 3 2004-05-01 The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
NCT00138008 ↗ Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Completed Haruhiko Fukuda Phase 3 2004-05-01 The purpose of this study is to evaluate radiotherapy followed by endocrine therapy in comparison with endocrine therapy alone for PSA failure after radical prostatectomy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Urologic G In Plastic Container

Condition Name

Condition Name for Urologic G In Plastic Container
Intervention Trials
Prostate Cancer 8
Pain, Postoperative 5
Bladder Cancer 4
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Urologic G In Plastic Container
Intervention Trials
Pain, Postoperative 12
Urinary Bladder Neoplasms 8
Syndrome 7
Prostatic Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Urologic G In Plastic Container

Trials by Country

Trials by Country for Urologic G In Plastic Container
Location Trials
United States 207
Japan 25
Canada 18
Korea, Republic of 6
France 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Urologic G In Plastic Container
Location Trials
New York 13
California 12
Texas 10
Michigan 10
Illinois 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Urologic G In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Urologic G In Plastic Container
Clinical Trial Phase Trials
Phase 4 38
Phase 3 17
Phase 2 13
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Urologic G In Plastic Container
Clinical Trial Phase Trials
Completed 50
Recruiting 16
Unknown status 14
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Urologic G In Plastic Container

Sponsor Name

Sponsor Name for Urologic G In Plastic Container
Sponsor Trials
National Cancer Institute (NCI) 4
University of Texas Southwestern Medical Center 4
Yonsei University 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Urologic G In Plastic Container
Sponsor Trials
Other 132
Industry 22
NIH 6
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Harvard Business School
Boehringer Ingelheim
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.